Goodbye androgen hypothesis, hello saturation model

European Urology

Volumn 62, Issue 5, 2012, Pages 765-767

  Morgentaler, Abraham ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANOLONE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANDROGEN BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ANDROGEN HYPOTHESIS; BONE METASTASIS; CANCER REGRESSION; CASTRATION; DIGITAL RECTAL EXAMINATION; EDITORIAL; HUMAN; HYPOTHESIS; PRIORITY JOURNAL; PROCESS MODEL; PROSTATE CANCER; SATURATION MODEL;

5-ALPHA REDUCTASE INHIBITORS; ANTINEOPLASTIC AGENTS, HORMONAL; AZASTEROIDS; DIHYDROTESTOSTERONE; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 84867077468     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.06.027     Document Type: Editorial

References (10)

1. R.L. Muller, L. Gerber, D.M. Moreira, G. Andriole, R. Castro-Santamaria, and S.J. Freedland Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the reduction by dutasteride of prostate cancer events trial Eur Urol 62 2012 757 764
2. C. Huggins, and C.V. Hodges Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Research 1 1941 293 297
3. A. Morgentaler, C.O. Bruning III, and W.C. DeWolf Incidence of occult prostate cancer among men with low total or free serum testosterone JAMA 276 1996 1904 1906
4. A. Morgentaler, and E.L. Rhoden Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen of 4.0 ng/ml or less Urology 68 2006 1263 1267
5. E.L. Rhoden, and A. Morgentaler Risks of testosterone-replacement therapy and recommendations for monitoring N Engl J Med 350 2004 482 492
6. A. Morgentaler Testosterone and prostate cancer: an historical perspective on a modern myth Eur Urol 50 2006 935 939
7. A. Morgentaler Testosterone replacement therapy and prostate cancer Urol Clin NA 34 2007 555 563
8. A. Morgentaler, and A.M. Traish Shifting the paradigm of testosterone and prostate cancer: the Saturation Model and the limits of androgen-dependent growth Eur Urol 55 2009 310 321
9. Garcia-Cruz E, Piqueras M, Huguet J, et al., Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment. Brit J Urol Int. In press. http://dx.doi.org/10.1111/j.1464-410X. 2012.11243.x.
10. Endogenous Hormones Prostate Cancer Collaborative Group, Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100:170-83.